Investigating the effect of target of rapamycin kinase inhibition on the Chlamydomonas reinhardtii phosphoproteome: from known homologs to new targets by Werth, Emily G. et al.
1 
 
Investigating the effect of Target of Rapamycin kinase inhibition on the Chlamydomonas 
reinhardtii phosphoproteome: from known homologs to new targets 
Emily G. Werth1, Evan W. McConnell1, Inmaculada Couso2,3, Zoee Perrine2, Jose L. Crespo3, 
James G. Umen2, and Leslie M. Hicks1 
1Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 
2Donald Danforth Plant Science Center, St. Louis, MO 63132, USA 
3 Instituto de Bioquímica Vegetal y Fotosíntesis, Consejo Superior de Investigaciones Científicas 
(CSIC)—Universidad de Sevilla; Avda. Américo Vespucio, 49, 41092 Sevilla, Spain 
Correspondence: Dr. Leslie M. Hicks, Department of Chemistry, University of North Carolina at 
Chapel Hill, 125 South Road, CB#3290, Chapel Hill, NC 27599 
E-mail: lmhicks@unc.edu 
Phone/Fax: 1-919-843-6903/919-962-2388 
Total word count: 5361 
Introduction: 736 
Materials and Methods: 1613 
Results: 1372 
Discussion: 1594 
Acknowledgements: 46 
Number of Tables: 2 
Number of Figures: 6, 5 in color 
Number of Supplemental Tables: 5 
Number of Supplemental Figures: 4 
 
 
 
 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/310102doi: bioRxiv preprint first posted online Apr. 28, 2018; 
2 
 
Summary 1 
• Target of Rapamycin (TOR) kinase is a conserved regulator of cell growth whose activity is 2 
modulated in response to nutrients, energy and stress. Key proteins involved in the pathway 3 
are conserved in the model photosynthetic microalga Chlamydomonas reinhardtii, but the 4 
substrates of TOR kinase and downstream signaling network have not been elucidated. Our 5 
study provides a new resource for investigating the phosphorylation networks governed by the 6 
TOR kinase pathway in Chlamydomonas. 7 
• We used quantitative phosphoproteomics to investigate the effects of inhibiting 8 
Chlamydomonas TOR kinase on dynamic protein phosphorylation. Wild-type and AZD-9 
insensitive Chlamydomonas strains were treated with TOR-specific chemical inhibitors 10 
(rapamycin, AZD8055 and Torin1), after which differentially affected phosphosites were 11 
identified.   12 
• Our quantitative phosphoproteomic dataset comprised 2,547 unique phosphosites from 1,432 13 
different proteins. Inhibition of TOR kinase caused significant quantitative changes in 14 
phosphorylation at 258 phosphosites, from 219 unique phosphopeptides. 15 
• Our results include Chlamydomonas homologs of TOR signaling-related proteins, including a 16 
site on RPS6 with a decrease in phosphorylation. Additionally, phosphosites on proteins 17 
involved in translation and carotenoid biosynthesis were identified. Follow-up experiments 18 
guided by these phosphoproteomic findings in lycopene beta/epsilon cyclase showed that 19 
carotenoid levels are affected by TORC1 inhibition and carotenoid production is under TOR 20 
control in algae. 21 
Keywords: Phosphoproteomics, Chlamydomonas, AZD8055, rapamycin, Torin1, target of 22 
rapamycin, TOR, NL  23 
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Introduction 24 
The Target of Rapamycin (TOR) protein kinase is a conserved eukaryotic growth regulator whose 25 
activity is modulated in response to stress, nutrients and energy supply (Wullschleger et al., 2006; 26 
Loewith & Hall, 2011; Dobrenel et al., 2016a; González & Hall, 2017; Pérez-Pérez et al., 2017). 27 
In metazoans and fungi, TOR is found in two compositionally and functionally distinct 28 
multiprotein complexes (TORC1) and (TORC2) that control rates of biosynthetic growth and 29 
cytoskeletal dynamics respectively (Raught et al., 2001; Wullschleger et al., 2006). In the green 30 
lineage (algae and land plants), only homologs of TORC1 proteins have been identified (Diaz-31 
Troya et al., 2008; van Dam et al., 2011; Dobrenel et al., 2016a). TORC1 kinase activity is 32 
modulated by nutrients and stress, and serves to control protein biosynthesis and other metabolic 33 
processes in response to environmental conditions (Raught et al., 2001). Selective chemical 34 
inhibitors of TOR kinase including rapamycin, AZD8055, and Torin1 have been instrumental in 35 
dissecting the TOR signaling pathway (Fingar & Blenis, 2004; Thoreen et al., 2009; Chresta et al., 36 
2010; Benjamin et al., 2011). Rapamycin (Rap) inhibits TORC1 activity through an allosteric 37 
mechanism requiring formation of a FKBP12-Rap complex (Heitman et al., 1991; Brown et al., 38 
1994; Sabatini et al., 1994).  Recent studies support the notion that several functions of TOR kinase 39 
are not inhibited by rapamycin (Thoreen et al., 2009). Instead, novel drugs like Torin1 and 40 
AZD8055 have been reported to more completely inhibit TOR kinase by acting as ATP-41 
competitors (Thoreen et al., 2009; Chresta et al., 2010). Torin1 has slower off-binding kinetics 42 
than other mTOR inhibitors in mammalian cell lines, possibly due to conformational change 43 
induction in the kinase that is energetically more difficult to recover from leading to a more 44 
pronounced and longer inhibition of the TORC1 pathway (Liu et al., 2013). AZD8055 is an ATP-45 
competitive inhibitor of mTOR and all PI3K class I isoforms noted to inhibit the mTORC1 and 46 
mTORC2 substrate phosphorylation (Roohi & Hojjat-Farsangi, 2017). These drugs were used to 47 
inhibit TOR activity in plants where rapamycin treatment is not highly effective (Zhang et al., 48 
2011; Montane & Menand, 2013).  49 
The role of TOR in mammalian and fungal cell metabolism has been extensively investigated 50 
(Wullschleger et al., 2006; Dibble & Manning, 2013; Saxton & Sabatini, 2017), while its role in 51 
photosynthetic eukaryotes is less well established (Zhang et al., 2013; Xiong & Sheen, 2014; 52 
Dobrenel et al., 2016a). TOR has been shown to control growth, metabolism and life span in the 53 
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model plant Arabidopsis thaliana (Arabidopsis) (Dobrenel et al., 2011; Ren et al., 2012; Xiong, 54 
Y. & Sheen, J., 2012; Xiong et al., 2013) where the TOR gene is essential (Menand et al., 2002). 55 
The model green alga Chlamydomonas reinhardtii (Chlamydomonas) has key TORC1 complex 56 
proteins encoded by single-copy genes including TOR (Cre09.g400553.t1.1), regulatory associate 57 
protein target of rapamycin (RAPTOR) (Cre08.g371957.t1.1), and lethal with sec-13 protein 8 58 
(LST8) (Cre17.g713900.t1.2) (Diaz-Troya et al., 2008; van Dam et al., 2011). Treatment of 59 
Chlamydomonas cultures with rapamycin has been shown to slow but not completely arrest cell 60 
growth (Crespo et al., 2005), activate autophagy (Perez-Perez et al., 2010), and induce lipid droplet 61 
formation (Imamura et al., 2015; Rodrigues et al., 2015). Recent work reported a connection 62 
between TOR kinase and inositol polyphosphate signaling that governs carbon metabolism and 63 
lipid accumulation (Couso et al., 2016). Chlamydomonas cells are sensitive to Torin1  and 64 
AZD8055 that are potent inhibitors of cell growth at saturating doses (Couso et al., 2016) and 65 
induce triacylglycerol accumulation (Imamura et al., 2016). However, the TOR pathway in 66 
Chlamydomonas has yet to be extensively characterized and, to date, only a limited number of 67 
candidate TOR kinase substrates have been identified.  68 
We characterized the phosphoproteome of Chlamydomonas that produced a conservative estimate 69 
of 4,588 phosphoproteins / 15,862 unique phosphosites (Wang et al., 2014) through a qualitative 70 
strategy involving extensive fractionation and complementary enrichment strategies, and have 71 
now developed label-free quantification (LFQ) to allow simultaneous quantification of 2,547 72 
Chlamydomonas phosphosites (Werth et al., 2017). Herein we characterized the effects of TOR 73 
inhibition on the Chlamydomonas phosphoproteome. Cultures treated with saturating doses of 74 
different TOR inhibitors (rapamycin, AZD8055 and Torin1) revealed hundreds of affected 75 
phosphosites with a significant overlap observed between those seen with different inhibitors. 76 
Phosphosites from an AZD-resistant mutant were compared with wild type after AZD treatment 77 
revealing very few potential off target effects.  Hierarchical clustering was used to classify sites 78 
and motif analysis was used to assess consensus motifs in clusters.    79 
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Materials and Methods 80 
Cell culturing and drug treatment. 81 
Strain CC-1690 wild-type mt+ (Sager 21 gr) (Sager, 1955) was used for the wild-type 82 
Chlamydomonas analysis across all chemical inhibitors. For the control AZD-insensitive strain 83 
experiments, strain was obtained from the Umen laboratory (Donald Danforth Plant Science 84 
Center). All cultures were maintained on TAP (Tris acetate phosphate) agar plates and grown in 85 
350-mL TAP liquid cultures at 25ºC as previously described (Couso et al., 2016). Experiments 86 
were done using five replicate cultures grown to exponential phase (1-2x106 cells/mL) for each 87 
drug condition and control and quenched with 40% methanol prior to harvesting by centrifuging 88 
at 4000 g for 5 min and discarding supernatant. To limit batch effects, replicate “n” of each drug 89 
and control were harvested together (Figure 1) prior to downstream processing. Cell pellets were 90 
then flash frozen using liquid nitrogen and stored at -80ºC until use. For AZD8055-, Torin 1-, and 91 
rapamycin- treated (LC Laboratories) cultures, drug was added to a final concentration of 500 nM 92 
for rapamycin and Torin 1, and 700 nM for AZD8055 from 1mM stocks in DMSO for 15 min 93 
prior to harvesting. For control replicates, just drug vehicle (DMSO) without a chemical inhibitor 94 
was added to each replicate culture for 15 min prior to harvesting. 95 
Protein extraction. 96 
Cell pellets were resuspended in lysis buffer containing 100 mM Tris, pH 8.0 with 1x 97 
concentrations of cOmplete protease inhibitor and phosSTOP phosphatase inhibitor cocktails 98 
(Roche, Indianapolis, IN, USA). Cells were lysed via sonication using an E220 focused 99 
ultrasonicator (Covaris, Woburn, MA, USA) for 120 s at 200 cycles/burst, 100 W power and 13% 100 
duty cycle. Following ultrasonication, the supernatant was collected from cellular debris by 101 
centrifugation for 10 min at 15,000 g at 4ºC and proteins were precipitated using 5 volumes of 102 
cold 100 mM ammonium acetate in methanol. Following 3 hr incubation at -80ºC, protein was 103 
pelleted by centrifugation for 5 min at 2,000 g followed by two washes with fresh 100 mM 104 
ammonium acetate in methanol and a final wash with 70% ethanol. Cell pellets were resuspended 105 
in 8M urea and protein concentration was determined using the CB-X assay (G-Biosciences, St. 106 
Louis, MO, USA). 107 
  108 
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Protein digestion and reduction. 109 
Samples were reduced using 10 mM dithiothreitol for 30 min at RT and subsequently alkylated 110 
with 40 mM iodoacetamide for 45 min in darkness at RT prior to overnight digestion. Samples 111 
were diluted 5-fold in 100 mM Tris following alkylation and digestion was performed at 25C for 112 
16 h with Trypsin Gold (Promega) at a protease:protein ratio of 1:50. 113 
Solid-phase extraction. 114 
After digestion, samples were acidified to pH<3.0 with trifluoroacetic acid (TFA). Pelleted, 115 
undigested protein was cleared from the supernatant by centrifugation for 5 min at 5,000 g prior 116 
to solid-phase extraction. Desalting was performed using C18 50 mg Sep-Pak cartridges (Waters). 117 
Columns were prepared by washing with acetonitrile (MeCN) followed by 80% 118 
MeCN/20%H2O/0.1% TFA and 0.1% TFA. Digested protein lysates were applied to the columns 119 
and reloaded twice before being washed with 0.1% TFA and eluted using 80% 120 
MeCN/20%H2O/0.1% TFA. 121 
Phosphopeptide enrichment and clean-up. 122 
Following protein digestion and solid-phase extraction, replicates were dried down using vacuum 123 
centrifugation and phosphopeptide enrichment was performed on 2-mg aliquots of each sample 124 
using 3 mg Titansphere Phos-TiO2 kit spin columns (GL Sciences) as previously described (Werth 125 
et al., 2017). After enrichment, samples were dried down and desalted again using ZipTips 126 
(Millipore) as per manufacturers protocol prior to LC-MS/MS acquisition. 127 
LC-MS/MS acquisition and data processing. 128 
Following ZipTip clean-up, peptides were dried down and resuspended in 20 µL of 0.1% TFA, 129 
5% MeCN before separation via a 90-min linear gradient from 95% H2O/5% MeCN/0.1% formic 130 
acid (FA) to 65% H2O/35% MeCN/0.1% FA via a NanoAcquity UPLC (Waters) using a C18 131 
column (NanoAcquity UPLC 1.8 μm HSS T3, 75 μm × 250 mm). A TripleTOF 5600 (AB Sciex) 132 
Q-TOF was operated in positive-ionization nanoelectrospray and high-sensitivity mode for data 133 
acquisition as previously described (Slade et al., 2015). In addition to the Supporting Information 134 
tables for MS datasets, the mass spectrometry proteomics data have been deposited to the 135 
ProteomeXChange Consortium via PRIDE partner repository(Vizcaíno et al., 2013) identifier 136 
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PXD007221. Acquired spectra (*.wiff) files were imported into Progenesis QI for proteomics 137 
(v2.0, Nonlinear Dynamics) as previously described (Werth et al., 2017) with peptide sequence 138 
determination and protein inference done by Mascot (v.2.5.1; Matrix Science) using the C. 139 
reinhardtii Phytozome v.11 database (www.phytozome.net/; accessed May 2015) appended with 140 
the NCBI chloroplast and mitochondrial databases (19,603 entries) and sequences for common 141 
laboratory contaminants (http://thegpm.org/cRAP/; 116 entries). For database searching, trypsin 142 
protease specificity with up to two missed cleavages, peptide/fragment mass tolerances of 20 143 
ppm/0.1 Da, a fixed modification of carbamidomethylation at cysteine, and variable modifications 144 
of acetylation at the protein N-terminus, oxidation at methionine, deamidation at asparagine or 145 
glutamine, phosphorylation at serine or threonine and phosphorylation at tyrosine were used. 146 
Peptide false discovery rates (FDR) were adjusted to ≤1% using the Mascot Percolator algorithm 147 
(Käll et al., 2007) and only peptides with a Mascot ion score over 13 were considered.  148 
Custom scripts written in Python were implemented to parse results following data normalization 149 
and quantification in Progenesis QI for proteomics. Shared peptides between proteins were 150 
grouped together to satisfy the principle of parsimony and represented in Table S1 by the protein 151 
accession with the highest amount of unique peptides, otherwise the largest confidence score 152 
assigned by Progenesis QI for proteomics. Additionally, the script appended site localization of 153 
variable modifications using an implementation of the Mascot Delta Score (Savitski et al., 2011) 154 
to the peptide measurements (*.csv) export from Progenesis QI for proteomics with confident site 155 
localization considered a Mascot Delta score >90%. Following scoring, only peptides with 156 
phosphorylation at serine, threonine, or tyrosine were considered for further processing and 157 
analysis. 158 
Downstream bioinformatics analysis. 159 
Missing value imputation was performed on logarithmized normalized abundances in Perseus 160 
v1.6.0.0 (Cox & Mann, 2012; Tyanova et al., 2016) requiring at least three of the five replicates 161 
in all drug conditions and control to be nonzero to continue through the workflow. A coefficient 162 
of variation (CV) cutoff was applied requiring CV<25% in at least 2 of 4 conditions for each 163 
phosphosite. For t-test analyses, replicates were grouped and the statistical tests were performed 164 
with fold change threshold of ±2 and p≤0.05 significance threshold. KEGG pathway annotation 165 
(Kanehisa & Goto, 2000), Gene Ontology (GO) (Ashburner et al., 2000) term annotation, 166 
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hierarchical clustering, and motif analysis were performed following statistical testing to glean 167 
biological insight on modulated sites found in the study. For hierarchical clustering, visualization 168 
was performed in Perseus v1.6.0.0. Following data normalization and missing value imputation, 169 
intensity values were z-score normalized and grouped using k-means clustering with default 170 
parameters. For motif analysis, sequence logo visualizations were performed using pLOGO with 171 
serine or threonine residues fixed at position 0. Positions with significant residue presence are 172 
depicted as amino acid letters sized above the red line (O'shea et al., 2013).  173 
Carotenoid analysis. 174 
Chlamydomonas cells were collected by centrifugation (4000 g for 5 min) and resuspended in 80% 175 
acetone. Samples were heat up for 5 min in a water bath at 90ºC and then centrifuge at 10000g 176 
10min. The supernatant evaporated under N2, and then resuspended in 80% acetone. The 177 
separation and chromatographic analysis of pigments was performed in a HPLC using a Waters 178 
Spherisorb ODS2 column (4.6 x 250 mm, 5µm particle size). The chromatographic method 179 
described by Baroli et al., 2003 (Baroli et al., 2003). Pigments were eluted at a flow rate of 1.0 mL 180 
min-1 with a linear gradient from 100% solvent A (acetonitrile:methanol:0.1mM Tris-HCl pH 8.0 181 
[84:2:14]) to 100% solvent B (methanol:ethyl acetate [68:32]) for 20 min, followed by 7 min of 182 
solvent B, then 1 min with a linear gradient from 100% solvent B to 100% solvent A, and finally 183 
6 min with solvent A. The carotenoids were detected at 440 nm using a Waters 2996 photodiode-184 
array detector. The different carotenoids were identified using standards from Sigma (USA) and 185 
DHI (Germany). This analysis was normalized by dry cell weight. Dry weight was determined by 186 
filtering an exact volume of microalgae culture (30 mL) on pre-targeted glass-fiber filters (1µm 187 
pore size). The filter was washed with a solution of ammonium formate (0.5 M) to remove salts 188 
and dried at 100 °C for 24 h. The dried filters were weighed in an analytical balance and the dry 189 
weight calculated by difference. 190 
SDS-PAGE and Western Blotting. 191 
Chlamydomonas cells from liquid cultures were collected by centrifugation (4000 g for 5 min), 192 
washed in 50 mM Tris-HCl (pH 7.5), 10 mM NaF, 10 mM NaN3, 10 mM p-nitrophenylphosphate, 193 
10 mM sodium pyrophosphate, and 10 mM b-glycerophosphate), and resuspended in a minimal 194 
volume of the same solution supplemented with Protease Inhibitor Cocktail (Sigma). Cells were 195 
lysed by two cycles of slow freezing to –80 °C followed by thawing at room temperature. The 196 
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soluble cell extract was separated from the insoluble fraction by centrifugation (15 000 g for 20 197 
min) in a microcentrifuge at 4 °C.  For immunoblot analyses, total protein extracts (20 μg) were 198 
subjected to 12% SDS–PAGE and then transferred to PVDF membranes (Millipore). Anti-P-199 
RPS6(Ser242) and anti-RPS6 primary antibodies were generated as described in Dobrenel et al., 200 
2016 (Dobrenel et al., 2016b)  and produced by Proteogenix, (France). Phospho-p70 S6 kinase 201 
(Thr(P)-389) polyclonal antibody (Cell Signaling, 9205) was used as described in Xiong et al., 202 
2012 (Xiong, Yan & Sheen, Jen, 2012). Primary antibodies were diluted 1:2000 and 1:1000 203 
respectively. Secondary anti-rabbit (Sigma) antibodies were diluted 1:5000 and 1:10 000, 204 
respectively, in phosphate-buffered saline (PBS) containing 0.1% (v/v) Tween-20 (Applichem) 205 
and 5% (w/v) milk powder. The Luminata Crescendo Millipore immunoblotting detection system 206 
(Millipore) was used to detect the proteins. Proteins were quantified with the Coomassie dye 207 
binding method (BioRad).  208 
Results 209 
Parameter selection for TORC1-specific inhibition. 210 
Previous studies in Chlamydomonas have shown rapamycin drug saturation ranging from 500 nM-211 
1µM (Crespo et al., 2005). For this study, 500 nM rapamycin was selected and saturating doses 212 
for Torin1 and AZD8055 in wild-type Chlamydomonas strain CC-1690 were determined using 213 
serial dilutions with previously published target concentrations (Couso et al., 2016). Growth 214 
inhibition saturated at 500 nM for Torin1 and 700 nM for AZD8055 (Supplemental Figure 1). 215 
While reports have shown phosphorylation changes as early as 2 minutes after rapamycin 216 
treatment (Rigbolt et al., 2014), a 15-minute time point was chosen based on the high number of 217 
changes seen in mammalian cell lines at this time point (Demirkan et al., 2011; Harder et al., 2014; 218 
Rigbolt et al., 2014) and to ensure reproducibility in treatment and harvesting across 20 samples 219 
(control, AZD8055-, Torin1-, and rapamycin-treated with n=5) from the early logarithmic phase 220 
of growth. Growth for each replicate was staggered, and to limit batch-effects replicates were 221 
harvested in sets, each containing a control sample and the three different drug-tested samples 222 
(Figure 1) prior to downstream processing.  223 
Prior rapamycin phosphoproteomic experiments in mammalian studies have shown that 224 
phosphopeptide ratios in general were not affected by normalization to protein levels at a 15 min 225 
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time point (Harder et al., 2014). To confirm this in Chlamydomonas reinhardtii, a whole-cell 226 
proteomics experiment (n=4) was performed after 15 min of rapamycin inhibition. These results 227 
showed that protein abundance levels in general are not affected with only 18 of the 1,539 proteins 228 
quantified significantly changing (Supplemental Table S4) with no significant differences in 229 
protein abundances between control and treatment (Supplemental Figure 2). While 4 of the 18 230 
proteins changing at the protein level were identified in the phosphoproteomics study detailed 231 
below, they were not detected as phospho-modulated following chemical inhibition and thus not 232 
proteins of interest in this study. Thus, we have confidence that the statistically significant 233 
phosphorylation sites detected are from changes in the phosphorylation status and not an artefact 234 
of protein expression or turnover. 235 
Quantitative coverage of the TOR-inhibited phosphoproteome. 236 
Label-free quantitative phosphoproteomics was used to compare normalized abundance values of 237 
control samples (n=5) versus samples treated with each of the chemical inhibitors (n=5) using an 238 
area under the curve (AUC) MS1 intensity-based quantitation method. For this approach, the 239 
change in chromatographic peak area between control and chemically-inhibited replicates for each 240 
phosphopeptide was the basis for determining relative phosphopeptide abundance. Tip-based TiO2 241 
phosphopeptide enrichment that previously showed high reproducibility between samples (Werth 242 
et al., 2017) was used for sample preparation. As part of the LFQ pipeline, quantitative data was 243 
filtered for only peptides containing a phosphorylation site on Ser, Thr, or Tyr after peak picking 244 
and peptide sequence determination. At least 3 of the 5 replicates for each condition were required 245 
to have nonzero abundances to remain in the final dataset presented in Table S1 and missing value 246 
imputation was performed on log-transformed normalized abundances (Cox & Mann, 2012; 247 
Tyanova et al., 2016). Highly variable sites remaining in the dataset were then removed by filtering 248 
out those with a coefficient of variation of >25% in >2 experimental conditions. The resulting 249 
dataset contained 2,547 unique phosphosites from 1,432 different proteins (Table S1) in untreated 250 
control samples. To determine sites of interest following chemical inhibition with Torin1, 251 
AZD8055, or rapamycin, two sample Student’s T-tests were performed between samples from 252 
each chemical inhibitor compared and control samples. From this, 258 phosphosites from 219 253 
phosphopeptides showed at least a two-fold change and a p-value ≤ 0.05 (Figure 2a, Table S2). 254 
High confidence phosphorylation site assignments (90% site-localization based on Mascot Delta 255 
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scoring(Savitski et al., 2011)) were achieved for 48% of the dataset (1,123 of the 2,363 256 
phosphopeptides) listed in Table S1. AZD8055 treatment resulted in 97 phosphopeptides 257 
modulated in the wild-type strain (Figure 2a). A matched control experiment using an AZD-258 
insensitive strain which grow similar to wild-type (Supplemental Figure 3) showed only 13 low 259 
abundance phosphosites differentially changing (Table S3, Figure 2b). Of the 13, no overlap was 260 
found with the 258 modulated phosphosites in the main dataset. 261 
Torin1 treatment caused the largest number of significant changes with 103 up- and 57 down-262 
modulated phosphosites. AZD8055 treatment caused 75 up- and 19 down-modulated 263 
phosphosites, while rapamycin treatment caused 40 up- and 35 down-modulated phosphosites. 264 
Overlap analysis of the differential sites for each drug revealed 88% (57/66) of all the down-265 
modulated sites were in the Torin1 subset, while 42% (24/57) of the Torin1 down-modulated sites 266 
were not detected with AZD or rapamycin. Up-regulated sites were also compared for each 267 
condition and to determine if the conditions had significant overlap between down- and up- 268 
modulated sites, a hypergeometric test was performed with p-values of 3.76x10-25 and 2.87 x10-34, 269 
respectively, showing significant overlap. 270 
Cluster analysis and phosphosite motif identification. 271 
Kinase specificity can be dictated by amino acid residues immediately surrounding 272 
phosphorylation sites on substrates (Chou & Schwartz, 2011). Mammalian TOR has been shown 273 
to mainly (but not exclusively) phosphorylate (S/T)P motifs and motifs with hydrophobic residues 274 
surrounding the phosphorylation site making it a relatively promiscuous kinase whose substrate 275 
choices may also be influenced by additional interactions outside the phosphosite region 276 
(Robitaille et al., 2013). Hierarchical clustering of Chlamydomonas modulated phosphosites 277 
generated 2 distinct clusters (Figure 3a,b), and motif analysis (O'shea et al., 2013) was performed 278 
on decreasing (cluster 1) and increasing (cluster 2) clusters . Cluster 1 phosphosites, which 279 
contained 94% of sites that significantly decrease in phosphorylation upon TOR inhibition, had 280 
significant enrichment for a proline in the +1 position and arginine in the -3 position with respect 281 
to the phosphorylation site (position 0) that showed strong enrichment for serine over threonine 282 
(Figure 3c). Cluster 2 phosphosites also had significant enrichment for a proline in the +1 position 283 
and arginine in the -3 position in addition to enrichment for an aspartic acid at the +3 position. 284 
Thus, CrTOR may have a preference for phosphorylation of (S/T)P motifs on substrates, similar 285 
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to mTOR(Robitaille et al., 2013) and other diverse proline-directed kinases including cyclin-286 
dependent protein kinases (CDKs) and mitogen-activated protein kinases (MAPKs) (Lu et al., 287 
2002). Additionally, a phosphoproteomic study using mammalian cell line MCF7 identified the 288 
RXXS/TP motif identified in clusters 1 and 2 as a rapamycin-sensitive motif (Rigbolt et al., 2014). 289 
Other studies have also found RXRXXS/T and RXXS/T motifs (Demirkan et al., 2011; Harder et 290 
al., 2014) enriched among rapamycin-sensitive phosphosites that are recognized by mTOR-291 
regulated kinases Akt, S6K1 and SGK1 (Hsu et al., 2011). Cluster 2 additionally has an acidic 292 
motif also found in casein kinase- II substrates (Lv et al., 2014). 293 
Phosphosites in TORC1 complex proteins.  294 
Numerous phosphosites in mammalian homologs of TORC1 complex proteins are regulated by 295 
the TOR pathway and/or are phosphorylated autocatalytically (Foster et al., 2010). This includes 296 
sites on Raptor and mTOR homologs. Therefore, phosphosites found on CrTORC1 complex 297 
proteins could be affected by TOR inhibition. TORC1 complex proteins conserved in 298 
Chlamydomonas include TOR (Cre09.g400553.t1.1), Raptor (Cre08.g371957.t1.1), and LST8 299 
(Cre17.g713900.t1.2) (Merchant et al., 2007; Diaz-Troya et al., 2008; Perez-Perez et al., 2010; 300 
Couso et al., 2016). While there is a known LST8 homolog in Chlamydomonas, it is not known to 301 
be phosphorylated (Wang et al., 2014). Phosphosites on Raptor (Ser782/783:NL) (Not 302 
Localized:NL) and TOR (Ser2598) were detected in this study, however no statistically significant 303 
modulation in their abundance was detected. BLASTP alignment of human Raptor (Uniprot 304 
Q8N122) with CrRaptor revealed high sequence overlap on the N-terminal region of the protein 305 
(residues 9-627 with 57% identity), however known TORC1-sensitive phosphosites in the human 306 
Raptor homolog (i.e. Ser719, Ser721, Ser722, Ser859, and Ser863 (Carrière et al., 2008; Foster et 307 
al., 2010)) were not conserved in CrRaptor. Similarly, human mTOR (Uniprot P42345) 308 
phosphosites Ser2159/Thr2164 that are within the kinase domain promoting mTORC1-associated 309 
mTOR Ser2481 autophosphorylation (Ekim et al., 2011) are not conserved in CrTOR. The limited 310 
sequence conservation among CrTORC1 phosphosites with mammalian TOR phosphosites 311 
precludes any predictions about functions of CrTORC1 protein phosphorylation. Other 312 
phosphosites on CrTORC1 complex proteins that were detected in previous work on the global 313 
phosphoproteome in Chlamydomonas (Wang et al., 2014) might be significant for regulation but 314 
they were not observed in our data. Future experiments with additional fractionation to increase 315 
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the dynamic range of quantitative coverage could allow for deeper coverage and more 316 
comprehensive detection of phosphosites. 317 
Discussion 318 
Sites modulated by TORC1 inhibition – known and putative substrates. 319 
In animal cells TORC1-inhibition blocks phosphorylation of multiple substrates including S6 320 
kinases and eukaryotic translation initiation factors, leading to a reduction in translation initiation 321 
rates for a subset of mRNAs (Jefferies et al., 1994; Terada et al., 1994; Wang & Proud, 2009). 322 
Phosphorylation of Ser371 and Thr389 in human p70S6K1 (Uniprot P23443-2) are reduced by 323 
treatment of cells with TOR inhibitors (Dennis et al., 1996; Burnett et al., 1998). While we 324 
identified one potential site (site was not localized) (Thr771/Ser773/Thr777:NL) on a 325 
Chlamydomonas homolog of ribosomal protein S6 kinase (S6K; Cre13.g579200.t1.2), its 326 
phosphorylation state was not significantly altered by TOR inhibitors (Table 1). No coverage was 327 
obtained on predicted conserved sites Ser915 and Thr932, which align to human p70S6K1 Ser371 328 
and Thr389, respectively, although these sites have been detected previously in Chlamydomonas 329 
(Wang et al., 2014). Moreover, while commercial anti-phospho S6K antibodies have been shown 330 
to detect phospho-S6K in plants (Xiong, Yan & Sheen, Jen, 2012; Ahn et al., 2014) they have not 331 
detected a signal in Chlamydomonas in our hands (Supplemental Figure 4) and in another study 332 
(Couso et al., 2016), thus limiting our ability to independently validate Chlamydomonas TOR 333 
substrate phosphopeptides. On the other hand, Chlamydomonas ribosomal protein S6 (RPS6, 334 
Cre09.g400650.t1.2), a predicted target of S6K, showed a 2.1-fold decrease in phosphorylation on 335 
Thr127 following Torin1 treatment (Figure 5, Table 1). While this site is potentially TORC1-336 
regulated, antibodies specific for this phosphosite needed for validation are not available. In 337 
Arabidopsis, a phosphosite on the C-terminal extremity peptide of RPS6, Ser240,  had decreased 338 
phosphorylation following TOR inactivation (Dobrenel et al., 2016b). While this exact site is not 339 
conserved in Chlamydomonas, the phosphoserine next to it, Ser241 in Arabidopsis (aligning to 340 
Ser242 in Chlamydomonas) has been detected in prior work (Wang et al., 2014); however it was 341 
not detected in this study (Figure 4a). To determine if Ser242 in Chlamydomonas is TORC1-342 
regulated, a western blot of proteins fractionated from wild-type cells under different drug 343 
treatments for 0, 5, 15, 30, and 60 min was performed with antibodies raised for phosphorylated 344 
and non-phosphorylated Ser242 (Figure 4b), the latter used as a control for monitoring protein 345 
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level. Interestingly, this site does not seem to change drastically with Torin1, AZD8055, or 346 
rapamycin treatment contrary to results on the C-terminal phosphosite in Arabidopsis. 347 
Sites modulated by TORC1 inhibition – known TOR pathway association. 348 
Of the 258 phosphosites detected as significantly modulated in this study, 10 are in homologs of 349 
proteins associated with the TOR signaling pathway (Figure 5, Table 1). In addition to four sites 350 
of decreasing phosphorylation, six proteins related to the TOR pathway had an increase in protein 351 
phosphorylation following chemical inhibition. While initially an unexpected observation, similar 352 
increases were previously reported for some phosphosites in a phosphoproteomic study of TOR 353 
inhibition in mouse liver (Demirkan et al., 2011). In our study, sites with increasing 354 
phosphorylation after TOR inhibition include elongation factor 2 (EEF2, Cre12.g516200.t1.2) 355 
whose animal homologs showed reduced activity upon phosphorylation. In human cells, 356 
phosphorylation of  EEF2 Thr57 by elongation factor 2 kinase (EEF2K, Cre17.g721850.t1.2) 357 
inactivates EEF2 activity, an essential factor for protein synthesis (Hizli et al., 2013). This site is 358 
conserved in Chlamydomonas EEF2 (Thr57/Thr59:NL) where we detect a 4.75-fold increase in 359 
phosphorylation with AZD8055 treatment with a predicted effect of reduced translation initiation 360 
rates. From these data we predict that CrTOR signaling may inhibit EEF2 kinase activity, and that 361 
this inhibition is relieved in the presence of TOR inhibitors. 362 
LA RNA-binding protein (LARP1, Cre10.g441200.t1.2) had two phosphosites that both 363 
underwent large decreases in phosphorylation upon treatment with the three chemical inhibitors. 364 
Ser817 was decreased 0.06AZD8055, 0.05Torin1, and 0.13RAP and Ser 737/738:NL was decreased 365 
0.08AZD8055 and 0.01Torin 1 but no change in rapamycin (0.99RAP) (Figure 5). In mammals, LARP1 366 
phosphorylation also requires mTORC1 (Hsu et al., 2011; Yu et al., 2011; Kang et al., 2013) with 367 
studies in human cell lines establishing LARP1 as a target of mTORC1 and S6K with non-368 
phosphorylated LARP1 interacting with both 5’ and 3’ UTRs of RP mRNAs and inhibiting their 369 
translation (Hong et al., 2017). Additional reports have shown LARP1 as a direct substrate of 370 
mTORC1 in mammalian cells with mTORC1 controlling Terminal Oligopyrimidine (TOP) 371 
mRNA translation via LARP1 (Fonseca et al., 2015; Hong et al., 2017). The dramatic modulation 372 
of LARP1 phosphorylation detected in our study indicates that LARP1 may have a parallel role in 373 
Chlamydomonas. The human LARP1 phosphosites are not conserved with those we found in 374 
Chlamydomonas. However, based on the NCBI conserved domain searching (Marchler-Bauer & 375 
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Bryant, 2004), the DM15 domain required for the interaction of LARP1 with mTORC1 in human 376 
cell lines is conserved in Chlamydomonas LARP1, and the phospho-Ser817 detected in our study 377 
is adjacent to the DM15 domain (877-915) in Chlamydomonas, a region in mammalian 378 
LARP1shown to be required for interaction with mTORC1 (Hong et al., 2017).  379 
Additional proteins with phosphosites altered by TORC1 inhibition 380 
The majority of differential phosphosites we identified were not previously linked to TOR 381 
signaling, including in Chlamydomonas. These include sites on a translation-related protein 382 
(Cre17.g696250.t1.1) and RNA-binding proteins (Cre10.g441200.t1.2, Cre10.g466450.t1.1, 383 
Cre16.g659150.t1.1, Cre16.g662702.t1.1 Cre17.g729150.t1.2). One of the most down-modulated 384 
proteins annotated as CTC-interacting domain 4 (CID4, Cre01.g063997.t1.1), has been shown to 385 
have an important function in regulation of translation and mRNA stability in eukaryotes (Bravo 386 
et al., 2005; Jiménez-López et al., 2015). CID4 had 2 sites, Ser441 (FC=0.2AZD8055, FC=0.14TORIN1) 387 
and Ser439/Ser441/Ser446:NL (FC=0.03AZD8055, FC=0.05TORIN1) with a large decrease in 388 
phosphorylation upon inhibitor treatment. While little is known about the relationship between this 389 
protein and TORC1 signaling, the CTC domain, more recently referred to as the MLLE domain 390 
(Jiménez-López & Guzmán, 2014), is also found in evolutionarily conserved Poly (A)-binding 391 
proteins (PABPs). The large decrease in CID4 phosphorylation seen upon inhibition of the 392 
CrTORC1 pathway in our study implies a potential role for TORC1 mediated control of 393 
translation, similar to other well-known TOR substrates.  394 
Another differential phosphosite of interest following TORC1 inhibition that was not previously 395 
linked to TOR regulation is a site on lycopene beta/epsilon cyclase protein (Cre04.g221550.t1.2--396 
Thr800/Ser802:NL). This phosphosite is significantly increased upon Torin1 treatment (FC=4.02) 397 
and the total protein level remained constant upon rapamycin treatment (Supplementary Table S4, 398 
FC=0.88). Lycopene beta/epsilon cyclases are required for carotenoid biosynthesis, carrying out 399 
cyclation of lycopene to yield α- and β- carotenes (Cunningham et al., 1996; Cunningham & Gantt, 400 
2001; Cordero et al., 2010) which have been shown to be high-value compounds participating in 401 
light harvesting and in the protection of the photosynthetic apparatus against photo-oxidation 402 
damage (Frank & Cogdell, 1996; Cunningham Jr & Gantt, 1998). Recently in rice, carotenoid 403 
content was shown to be significantly lower in an s6k1 mutant compared to wild-type (Sun et al., 404 
2016) revealing a potential connection between the TOR pathway and carotenoid production. To 405 
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further investigate the effect of TORC1 inhibition on carotenoid biosynthesis in Chlamydomonas 406 
based on our phosphoproteomic finding, carotenoid levels in AZD-, Torin1- and rapamycin-treated 407 
cells were assessed after eight hours of treatment with three biological and two technical replicates 408 
(Figure 6, Table 2). After eight hours of treatment, there was a significant increase in various 409 
carotenoids measured in TOR-inhibited samples including β-carotene, which is directly 410 
downstream of cyclase activity (Figure 6, Table 2). While the effects on carotenoid biosynthesis 411 
and secondary metabolism following TORC1 inhibition required eight hours to become detectable, 412 
this is the first evidence that carotenoid production is modulated by TOR signaling in algae. 413 
Additionally, altered cyclase protein levels are not likely responsible for this finding since previous 414 
studies showed no change in lycopene beta/epsilon cyclase protein level after up to 24 hours of 415 
nitrogen stress (Cunningham Jr & Gantt, 1998; Valledor et al., 2014), a condition that is 416 
metabolically similar to TOR inhibition (Perez-Perez et al., 2010; Roustan et al., 2017).  417 
Numerous phosphosites from proteins without Phytozome database descriptions were also found 418 
to be down-regulated upon CrTORC1 inhibition, including some sites with large decreases (>five-419 
fold). For all unannotated proteins, we searched for pfam, Panther, KOG, KEGG, KO, and GO 420 
pathway terms and domain conservation using Phytozome and NCBI annotations (Table S4). 421 
Numerous proteins had conserved domains including structural maintenance of chromosomes 422 
(Accession: cl25732), autophagy protein (Accession: cl27196), transmembrane proteins 423 
(Accession: cl24526), and small acidic protein (Accession: pfam15477). While the large changes 424 
upon chemical inhibition are potentially interesting, especially the five proteins containing sites 425 
with at least a five-fold decrease in phosphorylation (Cre03.g152150.t1.2, Cre06.g263250.t1.1, 426 
Cre11.g469150.t1.2, Cre05.g236650.t1.1, Cre13.g582800.t1.2), future targeted work would be 427 
required to infer biological significance to this observation. To aid in this, the fifty-eight modulated 428 
sites without Phytozome database annotation were also homology searched for best BLAST hit 429 
IDs in Volvox, Gonium, and Arabidopsis to find homologs among green lineage (Table S5) and 430 
Table S2 displays all of the experimentally derived sites modulated by AZD8055, Torin1, and/or 431 
rapamycin and will serve as a guide in follow-up studies.  432 
In summary, we obtained a candidate list of phosphosites modulated following TORC1 433 
inhibition. We achieved extensive coverage of the TOR-modulated phosphoproteome in 434 
Chlamydomonas using a quantitative label-free approach. Our approach was validated by the 435 
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overlap of phosphosites altered using different TOR inhibitors and by our identification of 436 
Chlamydomonas homologs of TOR signaling-related proteins such as RPS6 and LARP1 that had 437 
decreased phosphorylation upon TORC1 inhibition. Follow-up experiments guided by our 438 
phosphoproteomic findings in lycopene beta/epsilon cyclase showed that carotenoid levels are 439 
affected by TORC1 inhibition, the first evidence that carotenoid production is under TOR control 440 
in algae. Conserved TOR substrate motifs were also identified such as RXXS/TP and RXXS/TP. 441 
Our study provides a new resource for investigating the phosphorylation networks governed by 442 
the TOR kinase pathway in Chlamydomonas. 443 
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Tables 674 
Table 1: TOR targets identified with fold change values for drug condition versus control.  675 
 676 
Fold change values shaded red indicate a statistically significant increase in phosphopeptide 677 
abundance for specified drug treatment versus control. Fold change values shaded blue indicate a 678 
statistically significant decrease in phosphopeptide abudance for specified drug treatment versus 679 
control. Level of p-value statistical significance is denoted by p-value ≤ 0.05 (*) and ≤ 0.01 (**) 680 
    Fold-change 
 Accession Common Name Sites AZD8055 Torin1 Rapamycin 
CrTORC1 proteins 
 Cre09.g400553.t1.1 TOR S2598 0.99 0.90 1.12 
 Cre08.g371957.t1.1 RAPTOR S782/S783:NL 1.56 1.94 1.54 
homologs of known substrates 
 Cre13.g579200.t1.2 RPS6KB T771/S773/T777:NL 1.17 1.35 1.05 
 Cre09.g400650.t1.2 RPS6 T127 0.90 0.48** 0.61* 
homologs of TOR pathway-associated proteins 
 Cre10.g441200.t1.2 LARP1 T668/S670:NL 1.50 1.91* 1.96* 
   S737/738:NL 0.08** 0.01** 0.99 
   T809/S810:NL 0.41 0.46 0.81 
   S817 0.06** 0.05** 0.13** 
 Cre17.g721850.t1.2 EEF2K S306 0.75 0.42** 0.58 
   S589/S591:NL 1.13 1.24 1.20 
   S853/S857 2.00* 2.73** 1.69 
 Cre12.g516200.t1.2 EEF2 T57/T59:NL 4.75* 1.88 2.76 
 Cre12.g511850.t1.2 GSK3B S322 1.27 1.15 1.25* 
 Cre09.g391245.t1.1 ATG1 T802/S803:NL 1.80 1.65 1.53 
 Cre06.g251050.t1.1 PRKAA S699/S702:NL 0.64 0.29 0.97 
 Cre10.g457500.t1.1 PRKAB S25/S29:NL 1.67* 1.75 2.27** 
 Cre02.g100300.t1.1 PI-3K/PI-4-like T149/S150:NL 1.11 0.82 0.92 
 Cre05.g245550.t1.1 PI3KA S794 1.04 0.91 1.51 
 Cre06.g304650.t1.1 PI3KB2 S403 1.25 1.39 0.88 
   T478/S479/S482:NL 0.94 1.19 1.06 
 Cre03.g192000.t1.2 SEH1 S337 4.22 2.64 1.43 
 Cre02.g076900.t1.1 PRKG1 S71 2.20 1.54 1.59** 
   S71/S78:NL 1.44 1.76* 1.41 
   S126, S128 1.84 1.23 0.82 
   T857/T859:NL 1.12 0.97 0.98 
   T857/T859:NL 0.89 0.97 0.92 
   T857/T859/T863:NL 1.45 1.17 1.22* 
 Cre10.g461050.t1.2 ATP synthase A S378 1.25 0.79 0.94 
 Cre02.g076350.t1.2 ATP6B, ATPase S7/S8:NL 2.24 1.12 2.09** 
 Cre11.g468550.t1.2 ATP synthase G2 S7 2.52* 1.62* 2.33 
   S77 1.60 1.24 1.33 
*p-value ≤ 0.05 **p-value ≤ 0.01 
 
Up- 
 
 
Down- 
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Table 2: Carotenoid content in WT Chlamydomonas after 8 hours of treatment with Rapamycin, 681 
Torin1, or AZD8055 compared to control. 682 
  683 
Carotenoids Content (mg g-1 DW) 
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Figure Legends: 684 
Figure 1. Drug treatment and cell harvesting workflow in Chlamydomonas cells. Replicate “n” 685 
(1-5) of each drug condition and control were harvested together prior to downstream processing. 686 
To minimize inter-condition batch effects, “n” replicate of each condition was harvested together 687 
and frozen until protein extraction. 688 
Figure 2: Sites modulated by TOR inhibition. Results of differential analysis between each 689 
chemical inhibitor drug treatment compared to control for both wild-type (a) and AZD-690 
insensitive (b) Chlamydomonas strains. For comparison of overlap between the drug conditions 691 
in the WT dataset, a Pearson’s correlation was performed comparing all condition types. From 692 
this, the highest correlation among conditions was between AZD8055 and Torin1 at 0.986 and 693 
the lowest 3 were all drug inhibitor vs. controls.  694 
Figure 3. Hierarchical clustering of differentially changing sites into 2 clusters (a). Visualization 695 
was performed in Perseus v1.6.0.0. Following data normalization and missing value imputation, 696 
intensity values were z-score normalized and grouped using k-means clustering with default 697 
parameters. Overall trends in site intensity were graphed and colored based on intensity (b). For 698 
each of the two clusters, motif analysis was performed (c). Sequence logo visualizations were 699 
performed using pLOGO with serine or threonine residues fixed at position 0. Positions with 700 
significant residue presence are depicted as amino acid letters sized above the red line. For 701 
cluster 1, there was significant enrichment for a proline in the +1 position and arginine in the -3 702 
position, RXXS/TP. For cluster 2, there was again significant enrichment for a proline in the +1 703 
position and arginine in the -3 position in addition to an aspartic acid in the +3 position, 704 
RXXS/TPXD. 705 
Figure 4 Comparison of RPS6 protein sequence between Arabidopsis and Chlamydomonas (a). a 706 
western blot in wild-type under different drug treatments for 0, 5, 15, 30, and 60 min with 707 
antibodies raised for Ser242 (b).  708 
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Figure 5: Bar charts of 10 modulated phosphosites on TOR pathway-associated proteins based 709 
on homology. Level of p-value statistical significance is denoted by p-value ≤ 0.05 (*) and ≤ 710 
0.01 (**) 711 
Figure 6: Bar chart of carotenoid content in WT Chlamydomonas after 8 hours of treatment with 712 
Rapamycin, Torin1, or AZD8055 compared to control 713 
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